Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib
Jingran Ji, Anupam Mitra, D. Ross Camidge, Jonathan W. Riess
Topics & Concepts
AlectinibCrizotinibAnaplastic lymphoma kinaseALK inhibitorMedicineLung cancerCancer researchOncologyMalignant pleural effusionLung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment